Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bilibili Inc (BILI) vs CVS Health Corp (CVS) Price & Performance

Bilibili IncTrade
CVS Health CorpTrade

Price performance (Past 24H)

Key statistics

Bilibili Inc vs CVS Health Corp — how do they compare? Bilibili Inc trades at $17.68 (market cap $7.71B), while CVS Health Corp trades at $93.68 (market cap $122.36B). The key difference: CVS Health Corp is far larger — about 15.9× Bilibili Inc's market cap, and CVS Health Corp pays a 2.78% dividend while Bilibili Inc pays none. Which is the better fit depends on your goals.

BILICVS
Market Cap
$7.71B$122.36B
Sector
MediaHealth
52-Week High
$35.92$110.60
52-Week Low
$15.96$65.51
Enterprise Value
$5.54B$184.71B
Dividend Yield
2.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bilibili Inc

Bilibili (BILI) trades at $18.74, up 0.48% with neutral technical signals. The company reported strong Q1 2026 earnings of $0.19 per share, beating estimates, and maintains solid profitability with a 4.58% net margin. Recent news highlights a new $300 million share repurchase program and upcoming Q2 2026 results on August 27, 2026. Technical indicators show mixed signals with RSI neutral but moving averages bullish.

Bilibili presents a compelling investment case with consistent earnings beats and strong analyst support (83% buy ratings). However, risks include competitive pressures in China's video platform market and reliance on advertising revenue growth. The upcoming Q2 earnings report will be crucial for validating the company's monetization strategy and user engagement metrics.

CVS Health Corp

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bilibili Inc

Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.

Read more on BILI

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS